Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
Notice of Discontinuation of Development of CTX-177 (ONO-7018)
Chordia presents new data at the American Association for Cancer Research Annual Meeting 2025
Notice of Release of Transcript of Interim Financial Results Briefing for the Fiscal Year Ending August 31, 2025
For 2nd quarter FY8 2025 Financial Results Presentation
Chordia Therapeutics, Dec-Feb (2Q) Ordinary Profit Loss Narrows
Non-consolidated Financial Results for the Six Months Ended February 28, 2025 [Japanese GAAP]
Presentation of data from our pipeline at the American Association for Cancer Research Annual Meeting 2025
Chordia Therapeutics, Sep-Nov (1Q) Ordinary Profit Loss Widens
Non-consolidated Financial Results for the Three Months Ended November 30, 2024 [Japanese GAAP]
Rogocekib for the treatment of Refractory or Relapsed Acute Myologic Lymphoma(AML) has been granted Orphan Drug Designation (ODD) in the US by the FDA
By FISCO Corporation Notice of Distribution of Our Corporate Research Report
Corporate Governance Report
Announcement of International Nonproprietary Name (INN) for CTX-712
Chordia announces the Release of a Transcript of the Earnings Briefing for the Fiscal Year Ended August 2024
Fiscal year ended August 2024 Financial Results Presentation
Non-consolidated Financial Results for the Fiscal Year Ended August 31, 2024 [Japanese GAAP]
Chordia to Present Results of Phase 1 Clinical Trial of CLK Inhibitor CTX-712 at the 2024 The 86th Annual Meeting of the Japanese Society of Hematolog
Chordia Therapeutics Inc., The Current Fiscal Year's Net Income to Widen
Announcement of Presentation on Phase 1 Clinical Trial of CLK Inhibitor CTX-712 at the 86th Annual Meeting of the Japanese Society of Hematology